Last reviewed · How we verify
NCT04883021
A Pilot Study of Repetitive Transcranial Magnetic Stimulation for Treatment of Methamphetamine Use Disorders
NA trial testing Dual Target Theta Burst Stimulation in Methamphetamine Abuse. Withdrawn.
31 May 2021
Quick facts
| Lead sponsor | University of New Mexico |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 August 2020 |
| Primary completion | 31 May 2021 |
| Estimated completion | 31 May 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Dual Target Theta Burst Stimulation
Conditions studied
- Methamphetamine Abuse — all drugs for Methamphetamine Abuse →
Sponsor
University of New Mexico
Who can join
Adults 18 to 60, any sex, with Methamphetamine Abuse. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
We propose a single-arm clinical trial, with historical controls as a comparison group for select outcomes. Subjects with MAUD will receive 16 sessions of dual-target theta burst stimulation to the DLPFC and MPFC over 4 weeks. We will follow outcomes for 12 weeks. Outcomes include treatment retention, craving, self-reported MA or stimulant use, urine drug screen results, depressive symptoms, anxiety symptoms, sleep quality, quality of life, response inhibition, and functional connectivity. Magnetic resonance imaging (MRI) to measure functional connectivity at baseline and four weeks.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04883021
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Methamphetamine Abuse
Currently open trials in the same condition.
- NCT06721494 — A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamin · Phase 2 · recruiting
- NCT06496750 — Ketamine for Methamphetamine Use Disorder · Phase 2 · recruiting
- NCT06410196 — Mood and Decision-making in Methamphetamine Use Disorder · NA · recruiting
- NCT06233799 — Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder · Phase 3 · recruiting
- NCT05700994 — Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM) · NA · active not recruiting
Other University of New Mexico trials
Trials by the same sponsor.
- NCT07484906 — Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies · Phase 2 · withdrawn
- NCT07506395 — Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder · Phase 1 · not yet recruiting
- NCT07265973 — PREPARE: Perioperative REhabilitation Around Vaginal Prolapse RepAir Surgery for Recovery Enhancement · NA · recruiting
- NCT06982443 — Wellness, Alcohol, Vitals, and Emotions · NA · recruiting
- NCT06940609 — Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04883021 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of New Mexico
- Last refreshed: 30 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04883021.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing